Ontology highlight
ABSTRACT: Introduction
Psychosis in Alzheimer's disease (AD) is associated with grave clinical consequences including a precipitous cognitive decline and a hastened demise. These outcomes are aggravated by use of existing antipsychotic medications, which are also associated with cognitive decline and increased mortality; preclinical models that would develop new therapeutic approaches are desperately needed. The current report evaluates the ability of the neoteric antipsychotic, pimavanserin, to normalize hyperkinesis and sensorimotor gating in the novel catechol-O-methyltransferase (COMT) deleted P301L/COMT- and rTg(P301L)4510 models of psychotic AD, and the impact of pimavanserin on tau pathology.Methods
Female P301L/COMT- mice were behaviorally characterized for abnormaliti
SUBMITTER: Jimenez H
PROVIDER: S-EPMC8804623 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature